Trial Profile
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions [EXTENSION OF 700020910]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Nov 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus
- Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms XIENCE V: SPIRIT WOMEN Sub-study
- Sponsors Abbott Laboratories
- 06 May 2014 New trial record